Drug Development Pharma - March 8, 2016
MedImmune receives fast track designation
AstraZeneca’s global biologics research and development arm, MedImmune, has received Fast Track designation from the US Food and Drug Administration (FDA) for its investigational human monoclonal antibody (mAb), MEDI8852, for the treatment of patients hospitalised with Type A strain influenza. The FDA’s Fast Track programme is designed to expedite the development and review of drugs […]
Collaboration - August 10, 2015
MedImmune in strategic collaboration with Inovio Pharmaceuticals
MedImmune, AstraZeneca’s global biologics research and development arm, has entered into a license agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases. Under the agreement, MedImmune will acquire exclusive rights to Inovio’s INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. INO-3112, which […]
New Market - June 8, 2015
AZ’s Interest in Immuno-oncology Grows
AstraZeneca and Medimmune, AstraZeneca PLC’s global biologics research and development unit, gave a presentation on the company’s pipeline in the area of immuno-oncology at the recent American Society of Clinical Oncology meeting. Immuno-oncology involves programming or stimulating the body’s own immune system to attack cancer cells, according to BioSpace.com. The companies reported on a number of pipeline […]
Collaboration - March 28, 2015
Astra, Innate Sign Agreement
Innate Pharma has signed a co-development and commercialization agreement with AstraZeneca and MedImmune, AstraZeneca’s wholly-owned subsidiary. The deal focuses on the development of anti-NKG2A antibody, IPH2201, also in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor created by MedImmune, to fight cancer. The compound IPH2201 currently is in Phase II development. Under the terms of […]
Collaboration - February 24, 2015
MedImmune/NIST Team Up
Biopharmaceutical research company MedImmune and the U.S. Department of Commerce’s National Institute of Standards and Technology are partners in a five-year research and development project to produce new medications or therapies using biological instead of chemical components. MedImmune is U.K.-based AstraZeneca PLC’s biologics research and development unit . It will provide funding for seven scientists for the first year. Each of the scientists will work on a […]
Agreement - January 13, 2015
MedImmune, Omnis Connect
AstraZeneca’s global biologics research and development arm, MedImmune, has entered into a licensing agreement with Omnis Pharmaceuticals, a privately-held biotechnology company focused on the development of oncolytic viruses. This agreement will allow MedImmune to combine key agents from its investigational immunotherapy portfolio with Omnis’ lead investigational oncolytic virus program, a genetically engineered strain of vesicular […]
